Literature DB >> 354916

[Cardiotoxicity of mianserin, an antidepressant (author's transl)].

H Kopera, H Schenk.   

Abstract

The effect of mianserin on cardiac function was investigated on 60 adults with known heart disease, the drug previously having been shown not to influence the action of phenprocoumon. After satisfactory anticoagulation had been established, all patients were given additionally two different dosage regimens of mianserin or a placebo in a double-blind trial lasting three weeks. The dose was gradually increased to a maximal daily level of 30 mg or 60 mg, respectively, on the sixth day. Heart rate, blood pressure and electrocardiogram were obtained before and after mianserin had been added. There was no statistically significant difference between the three trial groups with respect to the three measured variables.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 354916     DOI: 10.1055/s-0028-1129266

Source DB:  PubMed          Journal:  Dtsch Med Wochenschr        ISSN: 0012-0472            Impact factor:   0.628


  3 in total

1.  Phenprocoumon requirement, whole blood coagulation time, bleeding time and plasma gamma-GT in patients receiving mianserin.

Authors:  H Kopera; H Schenk; S Stulemeijer
Journal:  Eur J Clin Pharmacol       Date:  1978-07-30       Impact factor: 2.953

Review 2.  Mianserin: a review of its pharmacological properties and therapeutic efficacy in depressive illness.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1978-10       Impact factor: 9.546

3.  A double-blind comparative trial with mianserin and amitriptyline in outpatients with major depressive disorders.

Authors:  J P Feighner; R S Jacobs; R E Jackson; G Hendrickson; C H Merideth; P D O'Meara
Journal:  Br J Clin Pharmacol       Date:  1983       Impact factor: 4.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.